Articles from: OncLive
The FDA has issued a complete response letter to Incyte Corporation stating that it cannot approve the biologics license application for retifanlimab for use...
-
The @US_FDA issued a complete response letter to Incyte Corporation stating that it cannot approve the BLA for retifanlimab for use in patients w/ locally advanced or metastatic SCAC who are intolerant of platinum-based chemotherapy #oncology https://t.co/hX8WKtif6d - view on twitter
More coverage:
#oncology
Health Canada has approved the BTK inhibitor zanubrutinib for use in the treatment of adult patients with mantle cell lymphoma who have previously received...
-
The regulatory decision to approve the BTK inhibitor zanubrutinib is based on data from 2 single-arm clinical trials. Across the trials, zanubrutinib elicited an ORR of 84% per IRC and 2014 Lugano classification. @UofT #lymsm https://t.co/RKFRVjxJTW https://t.co/RKFRVjxJTW - view on twitter
More coverage:
#lymsm
Karim Masrouha, MD, discusses the challenges of surgically removing chordoma...
-
WATCH: @kmasrouha, of @nyulangone, discusses the challenges of surgically removing chordoma tumors #oncology https://t.co/HoaOSeb4RC - view on twitter
More coverage:
#oncology
The FDA has issued an alert that evidence from the phase 3 OCEAN study of melphalan flufenamide, which was recently approved for use in...
-
ICYMI: In the OCEAN 3 trial investigators examined melphalan flufenamide & dexamethasone vs pomalidomide & dexamethasone in patients w/ R/R multiple myeloma who had received 2-4 prior lines of therapy @US_FDA #mmsm https://t.co/YTM2Bdj3b7 https://t.co/YTM2Bdj3b7 - view on twitter
More coverage:
#mmsm
Mashup Score:5
OncLiveChallenges Arise as Public Health and Scientific Communication Enters Uncharted Territory - 8 hours
Mashup Score:5
It is difficult to dispute that these are troubling times for government officials and public health...
-
It is difficult to dispute that these are troubling times for government officials and public health agencies. @DrMaurieMarkman @CancerCenter #COVID19 https://t.co/JhmU06H9kZ - view on twitter
More coverage:
#covid19
Mashup Score:1
OncLiveJoseph W. Kim Receives Prestigious 2021 Cancer Clinical Investigator Team Leadership Award - 8 hours
Mashup Score:1
Joseph W. Kim, MD, Associate Professor of Medicine at Yale Cancer Center, has received a 2021 Cancer Clinical Investigator Team Leadership Award from the...
-
Joseph W. Kim Receives Prestigious 2021 Cancer Clinical Investigator Team Leadership Award @Joseph_W_Kim @YaleCancer #oncology https://t.co/mTxMgo5ZYT - view on twitter
More coverage:
#oncology
Lyndsay Willmott, MD, discusses selecting among available PARP inhibitors for the treatment of patients with ovarian cancer based on genetic testing...
-
Lyndsay Willmott, MD, of @ArizonaOncology, discusses selecting among available PARP inhibitors for the treatment of patients with ovarian cancer based on genetic testing results #ovca https://t.co/PgVDlRwGcj - view on twitter
More coverage:
#ovca
Mashup Score:1
OncLiveFDA Warns of Increased Risk of Death With Melphalan Flufenamide in Multiple Myeloma - 10 hours
Mashup Score:1
The FDA has issued an alert that evidence from the phase 3 OCEAN study of melphalan flufenamide, which was recently approved for use in...
-
ICYMI: The @US_FDA has issued an alert that evidence from the phase 3 OCEAN study of melphalan flufenamide has indicated that the doublet resulted in an increased risk of death in this population. #mmsm https://t.co/rpEnBA7Lwa - view on twitter
More coverage:
#mmsm
Mashup Score:5
OncLiveDr. Tolaney on Key Findings From the ExteNET Trial in HER2+ Breast Cancer - 11 hours
Mashup Score:5
Sara M. Tolaney, MD, MPH, discusses data from the phase 3 ExteNET trial utilizing neratinib in the treatment of patients with HER2-positive breast...
-
WATCH: @stolaney1, of @DanaFarber, discusses data from the phase 3 ExteNET trial utilizing neratinib in the treatment of patients with HER2-positive breast cancer. #bcsm https://t.co/MngcTkWllS - view on twitter
More coverage:
#bcsm
The combination of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine with and without consolidative radiotherapy was found to have strong efficacy and favorable tolerability...
Overall, PET negativity rates were 87% at PET-2, 88% at PET-4, & 85% at the end of therapy in the combination of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine. @DrAnitaKumar @sloan_kettering @ASCO_pubs #lymsm https://t.co/o4UkaOfRog https://t.co/o4UkaOfRog - view on twitter